BioSpace News Archive

Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients

Patent protected FLEXITAB technology delivers flexible and precise dosing from a single extended release tablet

RAP technology combines selective disruption of fibrotic structures with production of new collagen in single non-invasive procedure

Biosight Ltd. announced that the United States Food & Drug Administration has granted Orphan Drug Designation to BST-236, an investigational novel antimetabolite, for the treatment of acute myeloid leukemia.

Aquestive Therapeutics, Inc. announced it has completed enrollment in a single dose crossover pharmacokinetic trial for Libervant™, which is in development for the management of select patients with refractory epilepsy who require treatment to control episodes of increased seizure activity, or “seizure clusters.” The Company also initiated a rolling New Drug Application submission for Libervant in May 2019 with the FDA.

BioMarin Pharmaceutical Inc. announced that Vimizim® has been approved by the National Medical Products Administration for the treatment of patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome.

Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients

Versatile modular design accommodates ever-changing workflows.

The funding will fuel RxRevu’s continued growth as the only independent provider of EHR-integrated tools that assist clinicians in prescribing the right medication at the lowest patient cost possible

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces the immediate appointment of Patrick Coyle as Vice President and Chief Financial Officer.